USP22在恶性肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2016.06.015

摘要/Abstract

摘要： 去泛素化酶从不同底物上移除泛素，起到调控蛋白质活性和维持细胞内环境稳态的作用。去泛素化酶在细胞的转录后修饰过程中发挥重要作用，当去泛素化酶调控机制出现异常则会引起不同类型疾病的发生。而异常表达特异性去泛素化酶22(USP22)常与癌症预后不良有关。本文就USP22在肿瘤中的研究现状进行综述。

关键词: 恶性肿瘤, 过表达, USP22

Abstract: Deubiquitylases remove ubiquitin moieties from different substrates to regulate protein activity and cell homeostasis.Since this posttranslational modification plays a role in several different cellular functions,its deregulation has been associated with different pathologies.Aberrant expression of Ubiquitin-Specific Peptidase 22(USP22)has been associated with poor cancer prognosis.This article reviews the research status of USP22.

Key words: Malignant tumor, Overexpression, USP22

中图分类号:

R730.43

王技军，综述，贺岩，审校. USP22在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2016, 30(6): 551-554.

WANG Jijun,HE Yan. The research progresses in USP22 in malignant tumors[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 551-554.

参考文献

1 Barlev NA,Liu L,Chehab NH,et al.Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases[J].Mol Cell,2001,8(6):1243-1254.
2 Bouchard C,Dittrich O,Kiermaier A,et al.Regulation of cyclin D2 gene expression by the Myc/Max/Mad network:Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter[J].Genes Dev,2001,15(16):2042-2047.
3 Daniel JA,Grant PA.Multi-tasking on chromatin with the SAGA coactivator complexes[J].Mutat Res,2007,618(1/2):135-148.
4 Henry KW,Wyce A,Lo WS,et al.Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation,mediated by SAGA-associated Ubp8[J].Genes Dev,2003,17(21):2648-2663.
5 Bonnet J,Wang CY,Baptista T,et al.The SAGA coactivator complex acts on the whole transcribed genome and is required for RNA polymerase II transcription[J].Genes Dev,2014,28(18):1999-2012.
6 Zhang XY,Pfeiffer HK,Thorne AW,et al.USP22,an hSAGA subunit and potential cancer stem cell marker,reverses the polycomb-catalyzed ubiquitylation of histone H2A[J].Cell Cycle,2008,7(11):1522-1524.
7 Poeck B,Fischer S,Gunning D,et al.Glial cells mediate target layer selection of retinal axons in the developing visual system of Drosophila[J].Neuro,2001,29(1):99-113.
8 Atanassov BS,Evrard YA,Multani AS,et al.Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance[J].Mol Cell,2009,35(3):352-364.
9 Lin Z,Yang H,Kong Q,et al.USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development[J].Mol Cell,2012,46(4):484-494.
10 Li L,Osdal T,Ho Y,et al.SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells[J].Cell stem cell,2014,15(4):431-446.
11 Atanassov BS,Dent SY.USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1[J].EMBO Rep,2011,12(9):924-930.
12 Kobayashi T,Iwamoto Y,Takashima K,et al.Deubiquitinating enzymes regulate Hes1 stability and neuronal differentiation[J].FEBS,2015,282(13):2411-2423.
13 Hong A,Lee JE,Chung KC,et al.Ubiquitin-specific protease 22(USP22)positively regulates RCAN1 protein levels through RCAN1 deubiquitination[J].Cell Physiol,2015,230(7):1651-1660.
14 Gao Y,Lin F,Xu P,et al.USP22 is a positive regulator of NFATc2 on promoting IL2 expression[J].FEBS Letters,2014,588(6):878-883.
15 Xiao H,Tian Y,Yang Y,et al.USP22 acts as an oncogene by regulating the stability of cyclooxygenase-2 in non-small cell lung cancer[J].BBRC,2015,460(3):703-708.
16 Wilson MA,Koutelou E,Hirsch C,et al.Ubp8 and SAGA regulate Snf1 AMP kinase activity[J].Mol Cell Biol,2011,31(15):3126-3135.
17 Zhang XY,Varthi M,Sykes SM,et al.The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell cycle progression[J].Mol Cell,2008,29(1):102-111.
18 Lv L,Xiao XY,Gu ZH,et al.Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells[J].Mol Cell Biochem,2011,346(1/2):11-21.
19 Ning Z,Wang A,Liang J,et al.USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via beta-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma[J].Int J Oncol,2014,45(4):1594-1608.
20 Li ZH,Yu Y,Du C,et al.RNA interference-mediated USP22 gene silencing promotes human brain glioma apoptosis and induces cell cycle arrest[J].Oncol Lett,2013,5(4):1290-1294.
21 Forbes SA,Bindal N,Bamford S,et al.COSMIC:mining complete cancer genomes in the catalogue of somatic mutations in cancer[J].Nucleic Acids Res,2011,39:945-950.
22 Liang JX,Ning Z,Gao W,et al.Ubiquitinspecific protease 22 induced autophagy is correlated with poor prognosis of pancreatic cancer[J].Oncol Rep,2014,32(6):2726-2734.
23 Chou J,Lin YC,Kim J,et al.Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis[J].Head Neck,2008,30(7):946-963.
24 Xiao J,Li Y,Zhang W,et al.miR-34b inhibits nasopharyngeal carcinoma cell proliferation by targeting ubiquitin-specific peptidase 22[J].Onco Targets Ther,2016,16(9):1525-1534.
25 Zhuang YJ,Liao ZW,Yu HW,et al.ShRNA-mediated silencing of the ubiquitin-specific protease 22 gene restrained cell progression and affected the Akt pathway in nasopharyngeal carcinoma[J].Cancer Biol Ther,2015,16(1):88-96.
26 Ning Z,Wang A,Liang J,et al.USP22 promotes epithelial-mesenchymal transition via the FAK pathway in pancreatic cancer cells[J].Oncol Rep,2014,32(4):1451-1458.
27 Liu YL,Yang YM,Xu H,et al.Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer[J].J Surg Oncol,2011,103(3):283-289.
28 Liu Y,Yang Y,Xu H,et al.Implication of USP22 in the regulation of BMI-1,c-Myc,p16INK4a,p14ARF,and cyclin D2 expression in primary colorectal carcinomas[J].Diagn Mol Pathol,2010,19(4):194-200.
29 Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics 2002[J].CA Cancer J Clin,2005,55(2):74-108.
30 Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
31 Tang B,Tang F,Li B,et al.High USP22 expression indicates poor prognosis in hepatocellular carcinoma[J].Oncotarget,2015,6(14):12654-12667.
32 Tang B,Liang X,Tang F,et al.Expression of USP22 and Survivin is an indicator of malignant behavior in hepatocellular carcinoma[J].Int J Oncol,2015,47(6):2208-2216.
33 Parkin DM,Pisani P,Ferlay J,et al.Estimates of the worldwide incidence of eighteen major cancers in 1985[J].Int J Cancer,1993,54(4):594-606.
34 He Y,Jin YJ,Zhang YH,et al.Ubiquitin-specific peptidase 22 overexpression may promote cancer progression and poor prognosis in human gastric carcinoma[J].Transl Res,2015,165(3):407-416.
35 Yang DD,Cui BB,Sun LY,et al.The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma[J].Cell Biochem Biophys,2011,61(3):703-710.
36 Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
37 Hu J,Liu YL,Piao SL,et al.Expression patterns of USP22 and potential targets BMI-1,PTEN,p-AKT in non-small-cell lung cancer[J].Lung Cancer,2012,77(3):593-599.
38 Ning J,Zhang J,Liu W,et al.Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer[J].Eur J Histochem,2012,56(4):e46.

[1]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[2]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[3]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[4]	韩滕综述, 唐丽萍审校. PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 468-470.
[5]	韩帮岭, 汪亦民, 薛英威. 中性粒细胞与恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 349-352.
[6]	周洁, 陈钰(综述), 陈道桢(审校). 纳米材料在肿瘤光动力治疗中的应用[J]. 实用肿瘤学杂志, 2018, 32(3): 245-249.
[7]	侯思宇(综述), 陈秀玮(审校). JMJD2B蛋白结构功能及在恶性肿瘤发生发展中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(3): 250-253.
[8]	张婷, 侯光营, 王鑫(综述), 贺岩(审校). QKI蛋白在恶性肿瘤中的研究进展及临床意义[J]. 实用肿瘤学杂志, 2018, 32(3): 263-266.
[9]	纪巧, 陈丽(综述), 何远桥(审校). 三维组织药敏法在肿瘤个体化精准医疗中的应用[J]. 实用肿瘤学杂志, 2018, 32(3): 280-284.
[10]	李静,张云艳. miR-331-3p在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 125-129.
[11]	张永欣, 黄河. Galectin-9与多种恶性肿瘤的研究进展及作用机制探讨[J]. 实用肿瘤学杂志, 2018, 32(2): 159-163.
[12]	吴逸飞, 刘宝刚. 硫氧还蛋白还原酶2在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 174-178.
[13]	韩雪娇, 李艳春, 孙立春, 鲁海玲审校. 14-3-3ζ与恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 543-547.
[14]	江莹, 刘宝刚审校. RCAN1在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 559-563.
[15]	孙禹琪,陈秀玮. CTGF/CCN2在恶性肿瘤的发生发展及靶向治疗中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 363-366.